Patents by Inventor Anna Demartis

Anna Demartis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small antibody-like polypeptides that bind to EPHA2 receptor
    Patent number: 10829558
    Abstract: The present disclosure is directed to a modified isolated immunoglobulin CH2 domain that specifically binds to an extracellular region of an EphA2 receptor, wherein the amino acid sequence of the modified immunoglobulin CH2 domain includes at least one amino acid substitution, addition or deletion in comparison to a wild type immunoglobulin CH2 domain amino acid sequence, wherein the wild type immunoglobulin CH2 domain amino acid sequence includes SEQ ID NO:1 or SEQ ID NO:2. Heterologous immunoconjugates including fusion proteins and pharmaceutical compositions including the modified isolated immunoglobulin CH2 domain are also disclosed. In addition, methods of treating a disease associated with EphA2 overexpression and methods for killing a target cell expressing EphA2 receptors using the modified isolated immunoglobulin CH2 domain are provided.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 10, 2020
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Kurt R. Gehlsen, Licia Tomei, Anna Demartis
  • Co-agonists of the glucagon and GLP-1 receptors
    Patent number: 10493125
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20180339017
    Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
    Type: Application
    Filed: December 5, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anandan Palani, Paul E. Carrington, Antonello Pessi, Armin Lahm, Elisabetta Bianchi, Anna Demartis
  • GENERATION AND CHARACTERIZATION OF ANTI-NOTCH ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC USE
    Publication number: 20110286916
    Abstract: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.
    Type: Application
    Filed: November 16, 2009
    Publication date: November 24, 2011
    Inventors: Jose Miguel Aste-Amezaga, Ningyan Zhang, Fubao Wang, Andrew Bett, Anna Demartis, Maurizio Nuzzo, Paolo Monaci, Stephen Blacklow, Jon Aster
  • Method of screening for anti-obesity agents using ciliary neutrophic factor receptor
    Patent number: 6960558
    Abstract: The present invention relates to methods for screening for anti-obesity agents using the ciliary neutrophic factor receptor.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: November 1, 2005
    Assignee: Instituto di Recerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Gennaro Ciliberto, Isabelle Gloaguen, Annalise Di Marco, Anna Demartis, Ralph Laufer, Riccardo Cortese
  • Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity
    Publication number: 20030176346
    Abstract: The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated diseases, for example hyperglycemia. FIG. 1 shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).
    Type: Application
    Filed: January 31, 2003
    Publication date: September 18, 2003
    Applicant: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Gennaro Ciliberto, Isabelle Gloaguen, Annalise Di Marco, Anna Demartis, Ralph Laufer, Riccardo Cortese